Governments and local organizations in America, Europe, and Australia are now beginning to fund vaccinations against human papilloma virus (HPV) program, following the WHO recommendation in 2009 that all women aged 9 to 13 years be vaccinated.

The HPV vaccines Gardasil (Merck&Co., Inc.) and Cervarix (GSK) have come to market in Korea, after receiving approval from the Korea Food & Drug Administration in June, 2007 and July, 2008, respectively. Korea has not yet introduced HPV vaccination into the national vaccination program, and there is ongoing disagreement on the subject of HPV vaccination among Korean academies. 

Two previous cost-benefit studies in Korea showed that the cost of a national HPV vaccination program is high compared with the benefits, leading to the conclusion that the vaccination program is not cost-effective with the current price of HPV vaccines. Considerable uncertainty remains, however, because insufficient data caused the previous studies to rely on some questionable assumptions. 

This study was performed with cost-utility analysis that is widely used to estimate the efficiency of HPV vaccination in the healthcare sector. This study also tried to elevate the completeness by incorporating data from the claims to the National Health Insurance (NHI) and from patient survey. 
The purpose of this study is to generate useful information for rational healthcare-policy decision-making by conducting the economic evaluation of a national HPV vaccination program from a societal perspective.